Replies to post #163311 on Biotech Values

[biomaven0]

If preferential inhibition of JAK1 can improve upon JAK1/2

Although in that case the Galapagos compound comes into play as well. There was some good discussion over on SI about the long-lasting metabolite of the Galapagos drug.

I personally have high hopes for a JAK1 drug in autoimmune disease. The basis for this is that inhibiting JAK1 in theory blocks STAT3, which in turn is one of the critical pathways for TH17, which I have come to believe is one of the key players in autoimmunity.

You can see the (complex) TH17 pathways here:

http://www.rndsystems.com/Pathway.aspx?p=15483&r=15436

Peter